keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/28521118/automated-cassette-based-production-of-high-specific-activity-203-212-pb-peptide-based-theranostic-radiopharmaceuticals-for-image-guided-radionuclide-therapy-for-cancer
#1
Mengshi Li, Xiuli Zhang, Thomas P Quinn, Dongyoul Lee, Dijie Liu, Falk Kunkel, Brian E Zimmerman, Daniel McAlister, Keith Olewein, Yusuf Menda, Saed Mirzadeh, Roy Copping, Frances L Johnson, Michael K Schultz
A method for preparation of Pb-212 and Pb-203 labeled chelator-modified peptide-based radiopharmaceuticals for cancer imaging and radionuclide therapy has been developed and adapted for automated clinical production. Pre-concentration and isolation of radioactive Pb2+ from interfering metals in dilute hydrochloric acid was optimized using a commercially-available Pb-specific chromatography resin packed in disposable plastic columns. The pre-concentrated radioactive Pb2+ is eluted in NaOAc buffer directly to the reaction vessel containing chelator-modified peptides...
May 10, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28514206/first-in-human-pet-ct-imaging-of-metastatic-neuroendocrine-neoplasms-with-cyclotron-produced-44-sc-dotatoc-a-proof-of-concept-study
#2
Aviral Singh, Nicholas P van der Meulen, Cristina Müller, Ingo Klette, Harshad R Kulkarni, Andreas Türler, Roger Schibli, Richard P Baum
(44)Sc is a promising positron emission tomography (PET) radionuclide (T1/2 = 4.04 hours, Eβ+average = 632 keV) and can be made available, using a cyclotron production route, in substantial quantities as a highly pure product. Herein, the authors report on a first-in-human PET/CT study using (44)Sc-DOTATOC prepared with cyclotron-produced (44)Sc. The production of (44)Sc was carried out through the (44)Ca(p,n)(44)Sc nuclear reaction at Paul Scherrer Institut, Switzerland. After separation, (44)Sc was shipped to Zentralklinik Bad Berka, Germany, where radiolabeling was performed, yielding radiochemically pure (44)Sc-DOTATOC...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28514062/locoregional-therapy-with-%C3%AE-emitting-trastuzumab-against-peritoneal-metastasis-of-her2-positive-gastric-cancer-in-mice
#3
Huizi Keiko Li, Yukie Morokoshi, Kotaro Nagatsu, Tadashi Kamada, Sumitaka Hasegawa
Peritoneal metastasis of gastric cancer (PMGC) is incurable and thus has an extremely poor prognosis. We have found however that locoregionally administered trastuzumab armed with a radionuclide astatine-211 ((211) At)-emitting α-particle ((211) At-trastuzumab) is effective against HER2-positive PMGC in a xenograft mouse model. We first observed that (211) At-trastuzumab can specifically bind and effectively kill NCI-N87 (N87) cells, which are HER2-positive human metastatic GC cells, both in vitro and in subcutaneous tumors...
May 17, 2017: Cancer Science
https://www.readbyqxmd.com/read/28508350/targeted-nuclear-imaging-probes-for-cardiac-amyloidosis
#4
REVIEW
Paco E Bravo, Sharmila Dorbala
PURPOSE OF REVIEW: The aim of the present manuscript is to review the latest advancements of radionuclide molecular imaging in the diagnosis and prognosis of individuals with cardiac amyloidosis. RECENT FINDINGS: (99m)Technetium labeled bone tracer scintigraphy had been known to image cardiac amyloidosis, since the 1980s; over the past decade, bone scintigraphy has been revived specifically to diagnose transthyretin cardiac amyloidosis. (18)F labeled and (11)C labeled amyloid binding radiotracers developed for imaging Alzheimer's disease, have been repurposed since 2013, to image light chain and transthyretin cardiac amyloidosis...
July 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28507988/comparative-therapeutic-efficacy-of-153-sm-edtmp-and-177-lu-edtmp-for-bone-pain-palliation-in-patients-with-skeletal-metastases-patients-pain-score-analysis-and-personalized-dosimetry
#5
Sarika Sharma, Baljinder Singh, Ashwani Koul, Bhagwant Rai Mittal
INTRODUCTION: The aim of the present study was to compare the therapeutic efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP in pain palliation in cancer patients with skeletal metastases. MATERIALS AND METHODS: Thirty patients (25 M:5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with documented skeletal metastases were recruited prospectively. Twenty patients were considered randomly for treatment with (153)Sm-EDTMP and with (177)Lu-EDTMP in 10 patients, respectively...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28493972/positive-radionuclide-imaging-of-mirna-expression-using-riles-and-the-human-sodium-iodide-symporter-as-reporter-gene-is-feasible-and-supports-a-protective-role-of-mirna-23a-in-response-to-muscular-atrophy
#6
Viorel Simion, Julien Sobilo, Rudy Clemoncon, Sharuja Natkunarajah, Safia Ezzine, Florence Abdallah, Stephanie Lerondel, Chantal Pichon, Patrick Baril
MicroRNAs (miRNAs) are key players in many biological processes and are considered as an emerging class of pharmacology drugs for diagnosis and therapy. However to fully exploit the therapeutic potential of miRNAs, it is becoming crucial to monitor their expression pattern using medical imaging modalities. Recently, we developed a method called RILES, for RNAi-Inducible Luciferase Expression System that relies on an engineered regulatable expression system to switch-ON the expression of the luciferase gene when a miRNA of interest is expressed in cells...
2017: PloS One
https://www.readbyqxmd.com/read/28488065/spect-imaging-and-radionuclide-therapy-of-glioma-using-131-i-labeled-buthus-martensii-karsch-chlorotoxin
#7
Wenli Qiao, Lingzhou Zhao, Shan Wu, Changcun Liu, Lilei Guo, Yan Xing, Jinhua Zhao
Gliomas, the most prevalent type of brain tumor in adults, are associated with high rates of morbidity and mortality. Recent studies on (131)I labeled scorpion toxins suggest they can be developed as tumor-specific agents for glioma diagnosis and treatment. This study investigated the potential of (131)I labeled Buthus martensii Karsch chlorotoxin ((131)I-BmK CT) as a new approach for targeted imaging and therapy of glioma. The results showed that (131)I can be successfully linked to BmK CT with satisfactory radiochemical purity and stability and that (131)I-BmK CT markedly inhibited glioma cell growth in a dose and time dependent manner, with significant accumulation in glioma cells in vitro...
May 9, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28485976/use-of-nanoparticle-contrast-agents-for-cell-tracking-with-computed-tomography
#8
Johoon Kim, Peter Chhour, Jessica Hsu, Harold I Litt, Victor A Ferrari, Rachela Popovtzer, David P Cormode
Efforts to develop novel cell-based therapies originated with the first bone marrow transplant on a leukemia patient in 1956. Preclinical and clinical examples of cell-based treatment strategies have shown promising results across many disciplines in medicine, with recent advances in immune cell therapies for cancer producing remarkable response rates, even in patients with multiple treatment failures. However, cell-based therapies suffer from inconsistent outcomes, motivating the search for tools that allow monitoring cell delivery and behavior in vivo...
May 9, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28483790/effect-of-hormone-secretory-syndromes-on-neuroendocrine-tumor-prognosis
#9
Wouter T Zandee, Kimberly Kamp, R C S van Adrichem, R A Feelders, Wouter W de Herder
The treatment of hormone hypersecretory syndromes caused by neuroendocrine tumors (NETs) can be a major challenge. NETs originating from the small intestine often secrete serotonin causing flushing, diarrhea and valve fibrosis, leading to dehydration or heart failure in severe cases. NETs from the pancreas can secrete a wider variety of hormones, like insulin, glucagon and gastrin leading to distinct clinical syndromes. Historically mortality in patients with functioning NETs was high due to the complications caused by the hypersecretion of hormones...
May 8, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28463538/targeted-radionuclide-therapy-an-evolution-toward-precision-cancer-treatment
#10
Hossein Jadvar
OBJECTIVE: This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. CONCLUSION: TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT...
May 2, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28451906/saul-hertz-md-and-the-birth-of-radionuclide-therapy
#11
EDITORIAL
Frederic H Fahey, Frederick D Grant, James H Thrall
The year, 2016, marked the 75th anniversary of Dr. Saul Hertz first using radioiodine to treat a patient with thyroid disease. In November of 1936, a luncheon was held of the faculty of Harvard Medical School where Karl Compton, PhD, president of the Massachusetts Institute of Technology was invited to give a presentation entitled "What Physics Can Do for Biology and Medicine." Saul Hertz who attended the luncheon spontaneously asked the very pertinent question that perhaps changed the course of treatment of thyroid disease, "Could iodine be made radioactive artificially?" We review the events leading up to the asking of this question, the preclinical investigations by Dr...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28450554/biodistribution-pharmacokinetics-and-dosimetry-of-177-lu-90-y-and-111-in-labeled-somatostatin-receptor-antagonist-ops201-in-comparison-to-the-agonist-177-lu-dota-tate-the-mass-effect
#12
Guillaume Pierre Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani
Radiolabeled somatostatin receptor (sstr) antagonists have shown in vivo higher uptake in sstr-expressing tumors than agonists. In this pre-clinical study the sstr2-antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) labeled with (177)Lu, (90)Y and (111)In was compared with the sstr2-agonist (177)Lu-DOTA-TATE. Methods: Biodistribution, pharmacokinetics, single-photon emission computed tomography/computed tomography (SPECT/CT) and dosimetry studies were performed to assess the bioequivalence of all radiotracers...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28446716/targeted-alpha-therapy-using-a-novel-cd70-targeted-thorium-227-conjugate-in-in-vitro-and-in-vivo-models-of-renal-cell-carcinoma
#13
Urs B Hagemann, Dessislava Mihaylova, Steinar R Uran, Joergen Borrebaek, Derek Grant, Roger M Bjerke, Jenny Karlsson, Alan S Cuthbertson
The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell carcinoma. We describe herein the characterization and efficacy of a novel CD70 targeted thorium-227 conjugate (CD70-TTC) comprising the combination of the three components, a CD70 targeting antibody, a chelator moiety and the short-range, high-energy alpha-emitting radionuclide thorium-227 (227Th). In vitro analysis demonstrated that the CD70-TTC retained binding affinity to its target and displayed potent and specific cytotoxicity compared to an isotype control-TTC...
April 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28438082/radioimmunoconjugates-for-treating-cancer-recent-advances-and-current-opportunities
#14
Mickaël Bourgeois, Clément Bailly, Mathieu Frindel, François Guerard, Michel Chérel, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Caroline Bodet-Milin
Radioimmunoconjugates have been used for 30 years to diagnose and treat cancer. For many years, the use of these therapeutic tools has been limited to haematological disorders, such as non-Hodgkin's lymphoma, given that they have only had a moderate effect on solid tumours. Areas covered: Recently, several strategies have revived the potential therapeutic application for radioimmunoconjugates. In this review, the authors review the advances in immunological engineering to develop new tools like monoclonal antibodies and their derivatives...
May 4, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28435455/the-netpet-score-combining-fdg-and-somatostatin-receptor-imaging-for-optimal-management-of-patients-with-metastatic-well-differentiated-neuroendocrine-tumors
#15
EDITORIAL
Elif Hindié
Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis. Metastatic well-differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to aggressive, even within apparently homogeneous categories. Thus, selecting the optimal treatment strategy is a challenging task. Somatostatin receptor imaging (SRI) is the standard molecular imaging technique for well-differentiated NET. When performed with (68)Ga-labeled somatostatin analogs (SRI-PET), it offers exquisite sensitivity for disease staging...
2017: Theranostics
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#16
Tessa Brabander, Wouter A Van der Zwan, Jaap Jm Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose<br /> Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival and toxicity of this therapy. <p>Patients and methods<br /> For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28427152/radioligand-therapy-of-metastatic-prostate-cancer-using-177lu-psma-617-after-radiation-exposure-to-223ra-dichloride
#17
Hojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, Rolf Fimmers, Stefan Kürpig, Elisabeth Eppard, Florian C Gaertner, Xiao Wei, Stefan Hauser, Markus Essler
Radioligand therapy with 177Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with 223Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of 177Lu-PSMA-617 after exposure to more cycles of 223Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with 223Ra...
February 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423213/systemic-tumor-targeted-sodium-iodide-symporter-nis-gene-therapy-of-hepatocellular-carcinoma-mediated-by-b6-peptide-polyplexes
#18
Sarah Urnauer, Kathrin Klutz, Geoffrey K Grünwald, Stephan Morys, Nathalie Schwenk, Christian Zach, Franz-Josef Gildehaus, Wolfgang Roedl, Manfred Ogris, Ernst Wagner, Christine Spitzweg
BACKGROUND: Non-viral polymer-based gene transfer represents an adaptable system for tumor-targeted gene therapy, as various design strategies of shuttle systems together with the mechanistic concept of active tumor targeting lead to improved gene delivery vectors resulting in higher tumor specificity, efficacy and safety. METHODS: Using the sodium iodide symporter (NIS) as theranostic gene, non-viral gene delivery vehicles based on linear polyethylenimine (LPEI), polyethylene glycol (PEG) and coupled with the synthetic peptide B6 (LPEI-PEG-B6), which specifically binds to tumor cells, were investigated in a hepatocellular carcinoma (HCC) xenograft model for tumor-selectivity and transduction efficiency...
April 19, 2017: Journal of Gene Medicine
https://www.readbyqxmd.com/read/28423195/noninvasive-imaging-of-c-rgd-2-9r-as-a-potential-delivery-carrier-for-transfection-of-sirna-in-malignant-tumors
#19
Xue Qi Chen, Meng Liu, Rong Fu Wang, Ping Yan, Chun Li Zhang, Chao Ma, Qian Zhao, Lei Yin, Guang Yu Zhao, Feng Qin Guo
The purpose of our study was to develop and evaluate a novel integrin αv β3 -specific delivery carrier for transfection of siRNA in malignant tumors. We adopted arginine-glycine-aspartate (RGD) motif as a tissue target for specific recognition of integrin αν β3 . A chimaeric peptide was synthesized by adding nonamer arginine residues (9R) at the carboxy terminus of cyclic-RGD dimer, designated as c(RGD)2 -9R, to enable siRNA binding. To test the applicability of the delivery carrier in vivo, c(RGD)2 -9R was labeled with radionuclide of technetium-99 m...
April 18, 2017: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28410143/targeted-radionuclide-therapy-frontiers-in-theranostics
#20
Francesca Gallivanone, Mauro Valente, Annarita Savi, Carla Canevari, Isabella Castiglioni
The concept of targeted radionuclide therapy (TRT) relies on the use of injected nuclear medicine as treating agents, targeted at the cellular or molecular level. The growth of the interest in TRT was stimulated by the advances in radionuclide production and labeling as well as by the improvement in the knowledge of appropriate and specific molecular targets. In recent years, different studies on TRT were focused on the evaluation of radionuclide compounds able to combine imaging of the disease with TRT, in a theranostic approach...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"